Total trials
221
Active
10
Phase 3
62
Total enrollment
49,199
Pipeline matrix
Showing 10 of 10 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Miebo | — | — | — | — | — | 3 | |
| Saline | — | — | — | — | — | 1 | |
| BL1107 Low dose | — | — | — | — | — | 1 | |
| BL1107 High dose | — | — | — | — | — | 1 | |
| Timolol maleate 0.5% | — | — | — | — | — | 1 | |
| Topical Ocular BL1332 low dose | — | — | — | — | — | 1 | |
| Topical Ocular BL1332 high dose | — | — | — | — | — | 1 | |
| BL1332 Vehicle ophthalmic vehicle | — | — | — | — | — | 1 | |
| BL1332 ophthalmic solution | — | — | — | — | — | 1 | |
| BL1332 ophthalmic vehicle | — | — | — | — | — | 1 |
Next readouts
- 2025-11
- 2026-05
- 2026-11
- 2027-02
Top conditions
- Cataract37
- Myopia34
- Inflammation15
- Astigmatism15
- Allergic Conjunctivitis12
- Pain11
- Ocular Hypertension8
- Dry Eye8
Frequently asked questions about Bausch & Lomb Incorporated
- How many clinical trials does Bausch & Lomb Incorporated have on ClinicalTrials.gov?
- Bausch & Lomb Incorporated is listed as the lead sponsor on 221 clinical trials in ClinicalTrials.gov, 10 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Bausch & Lomb Incorporated's trials are in Phase 3?
- 62 of Bausch & Lomb Incorporated's trials are in Phase 3, spread across 10 active drug programs.
- What therapeutic areas does Bausch & Lomb Incorporated focus on?
- Bausch & Lomb Incorporated's most-studied conditions on ClinicalTrials.gov are Cataract, Myopia, Inflammation, Astigmatism, Allergic Conjunctivitis.
- When are Bausch & Lomb Incorporated's next clinical trial readouts?
- Bausch & Lomb Incorporated has 4 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.”, expected around 2025-11.